Obesity and COVID-19
DOI:
https://doi.org/10.47196/diab.v56i3Sup.539Keywords:
obesity, COVID-19Abstract
The SARS-CoV-2 respiratory infection pandemic affected more than 317 million people, with approximately 5.5 million deaths worldwide due to the virus. Fifty percent of those who died from COVID-19-related causes had pre-existing cardiovascular or metabolic disease. Multiple publications have described the relationship of the virus with dysmetabolism and obesity, with visceral fat playing a leading role in the complications associated with both diseases. Epicardial and perivascular fat were also related to the severity observed in affected patients. Given the high prevalence of metabolic dysfunction and fatty liver disease (MAFLD), previously called non alcoholic fatty liver disease (NAFLD) in obese individuals, this entity was also associated with greater severity in patients with COVID-19.
References
I. Sanoudou D. Editorial: obesity, metabolic phenotypes and COVID-19. Metabolism Clinical and experimental 2022;128.
II. Cordeiro A, et al. Adipose tissue dysfunction and MAFLD in obesity on the scene of COVID-19. Clinics and research in hepatology and gastroenterology 2022;46.
III. Bil J, et al. The vicious cycle: a history of obesity and COVID-19. BMC Cardiovascular disorder 2021;21:332.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
